Coordinatore | DANMARKS TEKNISKE UNIVERSITET
Organization address
address: Anker Engelundsvej 1, Building 101A contact info |
Nazionalità Coordinatore | Denmark [DK] |
Totale costo | 8˙707˙431 € |
EC contributo | 5˙998˙788 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2011-two-stage |
Funding Scheme | CP-FP |
Anno di inizio | 2012 |
Periodo (anno-mese-giorno) | 2012-01-01 - 2015-12-31 |
# | ||||
---|---|---|---|---|
1 |
DANMARKS TEKNISKE UNIVERSITET
Organization address
address: Anker Engelundsvej 1, Building 101A contact info |
DK (KONGENS LYNGBY) | coordinator | 1˙849˙214.50 |
2 |
Unisensor A/S
Organization address
address: Gydevang 42 contact info |
DK (ALLEROD) | participant | 681˙010.00 |
3 |
FASTERIS SA
Organization address
address: CHEMIN DU PONT DU CENTENAIRE 109 contact info |
CH (PLAN LES OUATES) | participant | 670˙600.00 |
4 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 579˙783.00 |
5 |
GENOTYPE2PHENOTYPE LTD
Organization address
address: ST JUDES CHAMBERS 103A MANNINGHAM LANE contact info |
UK (BRADFORD) | participant | 493˙691.00 |
6 |
DIAGENODE
Organization address
address: RUE DU BOIS SAINT JEAN 3 LIEGE PARK SCIENCE contact info |
BE (SERAING) | participant | 481˙729.60 |
7 |
NIL TECHNOLOGY APS
Organization address
address: DIPLOMVEJ 381 contact info |
DK (KONGENS LYNGBY) | participant | 387˙600.00 |
8 |
BIOCOMPUTING PLATFORMS LTD OY
Organization address
address: TEKNIIKANTIE 14 contact info |
FI (ESPOO) | participant | 288˙200.00 |
9 |
FLUIGENT SA
Organization address
address: RUE DU FAUBOURG SAINT JACQUES 29 contact info |
FR (PARIS) | participant | 281˙060.00 |
10 |
PHILIPS ELECTRONICS NEDERLAND B.V.
Organization address
address: Boschdijk 525 contact info |
NL (EINDHOVEN) | participant | 273˙604.00 |
11 |
ROCHE DIAGNOSTICS GMBH
Organization address
address: Sandhofer Strasse 116 contact info |
DE (MANNHEIM) | participant | 12˙295.85 |
12 |
DNA ELECTRONICS LTD
Organization address
address: JOHN STREET 10 contact info |
UK (LONDON) | participant | 0.00 |
13 |
OXFORD NANOPORE TECHNOLOGIES LTD
Organization address
address: ROBERT ROBINSON AVENUE - OXFORD SCIENCE PARK 4 contact info |
UK (OXFORD) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'We propose a technology that will sit at the front-end of sequencing pipelines, present and future, and will significantly enhance the quality and throughput of DNA sequencing.
Although much attention has been given to throughput/cost of the sequencing process itself, the same cannot be said for the preparation of samples. Identified bottlenecks are (1) sequencing technologies require days of upfront sample preparation which is further increased when sequencing selected parts of the genome; (2) genome assembly relies on computationally intensive comparisons to the reference genome because existing technologies produce short sequence reads; (3) it is difficult to begin with small amounts of sample material comprising micro-biopsies and single cells.
The CELL-O-MATIC project will synergize efforts from SMEs, academics and large companies to address these bottlenecks by developing chip-based systems that process DNA from individual cells, ready for next generation high-throughput sequencing.
Single cell analysis has numerous applications in systems biology but we will emphasize DNA isolation and sequencing from circulating tumor cells (CTC), which have a strong prognostic value in cancer management.
A second innovation will be to develop methods that enable up to whole chromosome lengths of DNA to be contiguously mapped using nanofluidics. The inclusion of nanofluidics makes the project particularly distinctive and introduces European SMEs to an area that so far has been the domain of US companies.
A modular prototype comprising, a chip, fluid and thermal control, sonication and optical detection will be developed. Samples prepared using CELL-O-MATIC technology will be benchmarked in a high throughput environment with samples prepared by existing methods. Finally, the information obtained from the CELL-O-MATIC processed sample material will be validated for its utility as an aid to clinical decision making.'